We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVNA icon
126
Carvana
CVNA
$48.2B
$1.46M 0.34%
22,152
+2,292
+12% +$162K
NEM icon
127
Newmont
NEM
$131B
$1.45M 0.34%
15,528
+586
+4% +$63.8K
LGND icon
128
Ligand Pharmaceuticals
LGND
$5.52B
$1.44M 0.34%
4,551
+98
+2% +$23.1K
IBRX icon
129
ImmunityBio
IBRX
$8.63B
$1.43M 0.33%
163,786
-193,961
-54% -$1.47M
KNSA icon
130
Kiniksa Pharmaceuticals
KNSA
$5.86B
$1.43M 0.33%
22,411
+2,111
+10% +$110K
ASND icon
131
Ascendis Pharma A/S
ASND
$15.8B
$1.42M 0.33%
5,333
+1,503
+39% +$351K
CYTK icon
132
Cytokinetics
CYTK
$9.64B
$1.41M 0.33%
16,577
+12,274
+285% +$881K
CME icon
133
CME Group
CME
$98.9B
$1.41M 0.33%
6,394
-277
-4% -$76.6K
KURA icon
134
Kura Oncology
KURA
$1.01B
$1.41M 0.33%
128,495
+45,885
+56% +$433K
ACAD icon
135
Acadia Pharmaceuticals
ACAD
$4.61B
$1.4M 0.33%
55,139
+24,044
+77% +$529K
SNDX icon
136
Syndax Pharmaceuticals
SNDX
$1.62B
$1.39M 0.32%
63,720
+22,275
+54% +$463K
RIGL icon
137
Rigel Pharmaceuticals
RIGL
$829M
$1.38M 0.32%
35,400
+28,714
+429% +$886K
DNLI icon
138
Denali Therapeutics
DNLI
$3.26B
$1.38M 0.32%
53,688
+38,522
+254% +$792K
MIRM icon
139
Mirum Pharmaceuticals
MIRM
$6.1B
$1.37M 0.32%
11,705
-1,282
-10% -$129K
ROIV icon
140
Roivant Sciences
ROIV
$28.5B
$1.37M 0.32%
38,711
+509
+1% +$15K
SRPT icon
141
Sarepta Therapeutics
SRPT
$2.19B
$1.36M 0.32%
75,956
+36,743
+94% +$695K
KRYS icon
142
Krystal Biotech
KRYS
$9.97B
$1.36M 0.32%
3,657
+208
+6% +$62.1K
XERS icon
143
Xeris Biopharma Holdings
XERS
$1.37B
$1.36M 0.32%
171,264
+133,234
+350% +$851K
OXLC
144
Oxford Lane Capital
OXLC
$917M
$1.34M 0.31%
153,504
-55,143
-26% -$534K
NUVB icon
145
Nuvation Bio
NUVB
$2.04B
$1.34M 0.31%
236,358
+136,207
+136% +$666K
IRWD icon
146
Ironwood Pharmaceuticals
IRWD
$671M
$1.34M 0.31%
318,598
+242,429
+318% +$934K
BCRX icon
147
BioCryst Pharmaceuticals
BCRX
$2.09B
$1.34M 0.31%
133,664
+22,135
+20% +$200K
ZYME icon
148
Zymeworks
ZYME
$1.86B
$1.33M 0.31%
50,825
+40,123
+375% +$1.02M
HALO icon
149
Halozyme
HALO
$12.1B
$1.31M 0.31%
16,732
+3,161
+23% +$216K
LQDA icon
150
Liquidia Corp
LQDA
$5.88B
$1.3M 0.3%
16,326
+8,157
+100% +$437K
4 5
6
7 8

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.